Skip to content

Study · Non-randomized trial · n = 6 · 2010

8 results

Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation.

Perruccio K, Bonifazi P, Topini F, Tosti A, Bozza S, Aloisi T, Carotti A, Aversa F, Martelli MF, Romani L, Velardi A

Annals of the New York Academy of Sciences1 Apr 2010Cited by 24 (Europe PMC)

PMID20536464 (opens in a new tab)DOI10.1111/j.1749-6632.2010.05486.x (opens in a new tab)PepBankPUB-20536464
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    Five of six haploidentical transplant recipients who received thymosin alpha1 were alive and disease free at a median follow-up of 10 months.

    In plain wordsFive of six people who received thymosin alpha1 after a half-matched stem cell transplant were alive and disease free at a median of 10 months.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableSurvival and disease-free status at median 10 months
    Study

    n = 6

    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Five of six haploidentical transplant recipients who received Talpha1 are alive and disease free at a median follow-up of 10 months after transplantation (range: 5-20).
    1 context sentence
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  2. 02HumanNon-randomized trialSafety outcome

    Recipients who received thymosin alpha1 had only a single nonlethal infectious episode.

    In plain wordsPeople who received thymosin alpha1 after a transplant had only one infection, and it was not fatal.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableInfectious episodes
    Study

    n = 6

    Outcome group
    Adverse events · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    They experienced only a single nonlethal infectious episode and one patient developed fatal immune hemolytic anemia.
    2 context sentences
    Summary · context
    Five of six haploidentical transplant recipients who received Talpha1 are alive and disease free at a median follow-up of 10 months after transplantation (range: 5-20).
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  3. 03HumanNon-randomized trialSafety outcome

    One recipient who received thymosin alpha1 developed fatal immune hemolytic anemia.

    In plain wordsOne person who received thymosin alpha1 after a transplant developed fatal immune hemolytic anemia.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableFatal immune hemolytic anemia
    Study

    n = 6

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    one patient developed fatal immune hemolytic anemia.
    2 context sentences
    Summary · context
    Five of six haploidentical transplant recipients who received Talpha1 are alive and disease free at a median follow-up of 10 months after transplantation (range: 5-20).
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  4. 04HumanNon-randomized trialSafety outcome

    In recipients of haploidentical stem cell transplants for hematologic malignancies, thymosin alpha1 administration did not cause acute or chronic graft versus host disease.

    In plain wordsIn people receiving half-matched stem cell transplants, thymosin alpha1 did not cause acute or chronic graft versus host disease.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeAcute or chronic graft versus host disease
    Study

    n: not reported in source

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Talpha1 administration did not cause acute or chronic graft versus host disease
    1 context sentence
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  5. 05HumanNon-randomized trialEfficacy outcome

    In haploidentical transplant recipients, thymosin alpha1 administration was associated with significant improvement in polymorphonuclear cell phagocytosis.

    In plain wordsIn people receiving half-matched stem cell transplants, thymosin alpha1 was linked to better phagocytosis by white blood cells called polymorphonuclear cells.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreasePolymorphonuclear cell function (phagocytosis)
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    significant improvement in polymorphonuclear (phagocytosis) and dendritic cell (phagocytosis, expression of costimulatory molecules, and cytokine production) functions.
    1 context sentence
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  6. 06HumanNon-randomized trialEfficacy outcome

    In haploidentical transplant recipients, thymosin alpha1 administration was associated with significant improvement in dendritic cell phagocytosis, costimulatory molecule expression and cytokine production.

    In plain wordsIn people receiving half-matched stem cell transplants, thymosin alpha1 was linked to better dendritic cell function.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseDendritic cell function (phagocytosis, costimulatory molecules, cytokine production)
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    significant improvement in polymorphonuclear (phagocytosis) and dendritic cell (phagocytosis, expression of costimulatory molecules, and cytokine production) functions.
    1 context sentence
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  7. 07HumanNon-randomized trialEfficacy outcome

    In haploidentical transplant recipients, thymosin alpha1 administration was associated with increased T-cell counts.

    In plain wordsIn people receiving half-matched stem cell transplants, thymosin alpha1 was linked to higher T-cell counts.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseT-cell counts
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was also associated with increased T-cell counts and earlier appearance of functional pathogen-specific T cell responses (by a sensitive limiting dilution assay that detects frequency of T cells specific for Aspergillus, Candida, CMV, ADV, VZV, HSV, Toxoplasma).
    1 context sentence
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.
  8. 08HumanNon-randomized trialEfficacy outcome

    In haploidentical transplant recipients, thymosin alpha1 administration was associated with earlier appearance of functional pathogen-specific T-cell responses.

    In plain wordsIn people receiving half-matched stem cell transplants, thymosin alpha1 was linked to earlier T-cell responses against germs.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseAppearance of functional pathogen-specific T-cell responses
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was also associated with increased T-cell counts and earlier appearance of functional pathogen-specific T cell responses (by a sensitive limiting dilution assay that detects frequency of T cells specific for Aspergillus, Candida, CMV, ADV, VZV, HSV, Toxoplasma).
    1 context sentence
    Summary · context
    We designed a phase I/II clinical study to determine safety and efficacy of thymosin alpha1 (Talpha1) administration in recipients of one HLA haplotype (haploidentical) stem cell transplants for hematologic malignancies.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.